3 completed. 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 3 |
Follow CUDC-907: new trials by email Literature Review of CUDC-907 trials Research Report on CUDC-907
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma CUDC-907 - Lymphoma, Neuroblastoma | Phase 1 | Completed | Dana-Farber Cancer Institute | 26 | 2016-10-01 | 2026-02-11 |
| Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid Tumors CUDC-907 - Triple-Negative Breast Cancer, High-grade Serous Ovarian Cancer | Phase 1 | Completed | Curis, Inc. | 43 | 2014-11-01 | 2019-09-03 |
| Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma fimepinostat, Rituximab, venetoclax - Lymphoma, Relapsed Lymphoma | Phase 1 | Completed | Curis, Inc. | 106 | 2012-12-01 | 2021-05-06 |
Lymphoma (2) · Brain Neoplasms (1) · Lymphoma, Large B-Cell, Diffuse (1) · Neuroblastoma (1) · Triple Negative Breast Neoplasms (1)
Curis, Inc. (2) · Dana-Farber Cancer Institute (1)
United States (3)